IPF and PDE4B Inhibitors

EP: 1.Emerging Agents in IPF Treatment

Now Viewing

EP: 2.IPF and PDE4B Inhibitors

EP: 3.Importance of Patient-Reported Outcomes

EP: 4.Future Possibilities in IPF Treatment

EP: 5.Advice for Clinicians Treating IPF

EP: 6.Current Standard of Care in IPF

EP: 7.Therapeutic Response and Disease Progression

EP: 8.Key Considerations for Selecting IPF Treatment

EP: 9.Economic Impact of IPF

EP: 10.Unmet Needs in IPF Landscape

EP: 11.Overview of Idiopathic Pulmonary Fibrosis (IPF)

EP: 12.Impact of IPF on Quality of Life and Financial Considerations

EP: 13.Diagnosing IPF: Key Tests, Time to Diagnosis, and Importance of Early Detection

EP: 14.Clinical Presentation and Risk Factors

EP: 15.Impact of Comorbidities on IPF Management

EP: 16.Overcoming Treatment Barriers: Strategies for Success

EP: 17.Impact of Treatment Delays on Patient Outcomes

Video content above is prompted by the following:

• What is the rationale for studying the phosphodiesterase 4 (PDE4) inhibitor pathway in idiopathic pulmonary fibrosis (IPF)?
• How do PDE4 inhibitors differ from PDE4B inhibitors?
• Why is this pathway of interest to pulmonologists and patients living with IPF?